Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy (ENCORE)
Phase II Study of Cetuximab Combined With Intensity Modulated Radiotherapy (IMRT) and Concurrent Chemotherapy of Cisplatin in Nasopharyngeal Carcinoma
Sponsor: Cancer Hospital of Guizhou Province
This PHASE2 trial investigates Nasopharyngeal Carcinoma and is currently completed. Cancer Hospital of Guizhou Province leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Hospital of Guizhou Province
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Central South University
- First Affiliated Hospital of Guangxi Medical University
- Fudan University
- Fujian Cancer Hospital
- Sichuan Cancer Hospital and Research Institute
- Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .